GlassScriptPhysician profile
Ralph D Larsen
NPI 1306824149
$1,873.65
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $192 · 2021: $530 · 2022: $542.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $593.01 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $228.99 | 2019-2022 | |
| Myovant Sciences INC. | $189.10 | 2021-2022 | |
| Boston Scientific Corporation | $160.83 | 2019 | |
| 180 Medical, INC. | $150.15 | 2019-2022 | |
| Urovant Sciences INC | $111.20 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $65.42 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $61.13 | 2019 | |
| Blue Earth Diagnostics | $59.86 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $52.25 | 2021-2022 | |
| Rochester Medical Corporation | $49.98 | 2022 | |
| Antares Pharma, INC. | $27.80 | 2019-2020 | |
| Coloplast Corp | $27.34 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $25.76 | 2020 | |
| Pfizer INC. | $23.31 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $19.73 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.44 | 2021 | |
| Urogen Pharma, INC. | $13.35 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.